Image used with permission from nephrotox.com.

THE BURDEN OF URATE REMOVAL FALLS ON THE KIDNEYS

Uric acid elimination is highly inefficient even in healthy kidneys—only 10% of uric acid filtered through the kidney is excreted1

Artist’s rendition.

Urate reabsorbed

Urate excreted

During evolution, humans lost the enzyme uricase2

  • Unable to self-convert uric acid into allantoin (a water-soluble purine metabolite), humans rely on the kidneys for ~70% of their daily uric acid excretion
  • 90% of hyperuricemia is a result of underexcretion of uric acid by the kidneys1

Declines in renal function impact uric acid clearance3

EVEN WITH HIGH DOSES OF ORAL ULTs MANY PATIENTS STRUGGLE TO SUFFICIENTLY LOWER THEIR sUA LEVEL4-6

Percentage of patients treated with febuxostat and allopurinol who reached target sUA level6,7

FEBUXOSTAT 80 mg VS ALLOPURINOL 300 mg CLINICAL TRIAL (STUDY 3)6,7*
Target sUA (mg/dL)
FEB 80 mg (n=256)
ALLO 300 mg (n=253)
Primary endpoint: <6.0
Last 3 monthly measurements
53% 21%
<5.0*
At final visit
47% 13%
<4.0*
At final visit
20% 2%

*Post hoc analysis.

ULT=urate-lowering therapy.

  • The pooled phase 3 results for the percentage of patients with an sUA level <6 mg/dL at final visit for febuxostat 80 mg was 70%7,8

A DIFFERENT APPROACH: KRYSTEXXA IS A RECOMBINANT URICASE ENZYME THAT CONVERTS URATE INTO ALLANTOIN14

Artist’s rendition.

URATE

KRYSTEXXA

ALLANTOIN

KRYSTEXXA is indicated for the treatment of chronic gout in adult patients who have failed to normalize serum uric acid and whose signs and symptoms are inadequately controlled with xanthine oxidase inhibitors at the maximum medically appropriate dose or for whom these drugs are contraindicated.

IMPORTANT LIMITATIONS OF USE

  • KRYSTEXXA is not recommended for the treatment of asymptomatic hyperuricemia

RENAL EXCRETION OF ALLANTOIN IS UP TO 10 TIMES MORE EFFICIENT THAN EXCRETION OF URIC ACID18

Nearly all of allantoin filtered through the kidney is excreted1,18

Artist’s rendition.

Allantoin reabsorbed

Allantoin excreted

SELECT IMPORTANT SAFETY INFORMATION

  • Screen patients for G6PD deficiency prior to starting KRYSTEXXA. Hemolysis and methemoglobinemia have been reported with KRYSTEXXA in patients with G6PD deficiency. Do not administer KRYSTEXXA to these patients
  • Anaphylaxis may occur with any infusion, including a first infusion, and generally manifests within 2 hours of the infusion
  • KRYSTEXXA should be administered in healthcare settings and by healthcare providers prepared to manage anaphylaxis and infusion reactions

MONITORING
PROTOCOL

In a post hoc analysis, preinfusion sUA was revealed as a powerful biomarker for predicting infusion reactions. From this, a simple monitoring protocol was established.

All GOUT IS
TOPHACEOUS9,24-30

Experience the latest findings on gout progression through an interactive presentation, and see what processes can occur in gout independent of pain.

INDICATIONS AND USAGE

KRYSTEXXA® (pegloticase) is indicated for the treatment of chronic gout in adult patients who have failed to normalize serum uric acid and whose signs and symptoms are inadequately controlled with xanthine oxidase inhibitors at the maximum medically appropriate dose or for whom these drugs are contraindicated.

Important Limitations of Use: KRYSTEXXA is not recommended for the treatment of asymptomatic hyperuricemia.

Important Safety Information

WARNING: ANAPHYLAXIS AND INFUSION REACTIONS

Anaphylaxis and infusion reactions have been reported to occur during and after administration of KRYSTEXXA. Anaphylaxis may occur with any infusion, including a first infusion, and generally manifests within 2 hours of the infusion. However, delayed-type hypersensitivity reactions have also been reported. KRYSTEXXA should be administered in healthcare settings and by healthcare providers prepared to manage anaphylaxis and infusion reactions. Patients should be premedicated with antihistamines and corticosteroids. Patients should be closely monitored for an appropriate period of time for anaphylaxis after administration of KRYSTEXXA. Monitor serum uric acid levels prior to infusions and consider discontinuing treatment if levels increase to above 6 mg/dL, particularly when 2 consecutive levels above 6 mg/dL are observed.

CONTRAINDICATIONS: G6PD DEFICIENCY ASSOCIATED HEMOLYSIS AND METHEMOGLOBINEMIA

Screen patients for G6PD deficiency prior to starting KRYSTEXXA. Hemolysis and methemoglobinemia have been reported with KRYSTEXXA in patients with G6PD deficiency. Do not administer KRYSTEXXA to these patients.

INDICATIONS AND USAGE

KRYSTEXXA® (pegloticase) is indicated for the treatment of chronic gout in adult patients who have failed to normalize serum uric acid and whose signs and symptoms are inadequately controlled with xanthine oxidase inhibitors at the maximum medically appropriate dose or for whom these drugs are contraindicated.

Important Limitations of Use: KRYSTEXXA is not recommended for the treatment of asymptomatic hyperuricemia.

IMPORTANT SAFETY INFORMATION

WARNING: ANAPHYLAXIS AND INFUSION REACTIONS

Anaphylaxis and infusion reactions have been reported to occur during and after administration of KRYSTEXXA. Anaphylaxis may occur with any infusion, including a first infusion, and generally manifests within 2 hours of the infusion. However, delayed-type hypersensitivity reactions have also been reported. KRYSTEXXA should be administered in healthcare settings and by healthcare providers prepared to manage anaphylaxis and infusion reactions. Patients should be premedicated with antihistamines and corticosteroids. Patients should be closely monitored for an appropriate period of time for anaphylaxis after administration of KRYSTEXXA. Monitor serum uric acid levels prior to infusions and consider discontinuing treatment if levels increase to above 6 mg/dL, particularly when 2 consecutive levels above 6 mg/dL are observed.

The risk of anaphylaxis and infusion reactions is higher in patients who have lost therapeutic response.

Concomitant use of KRYSTEXXA and oral urate-lowering agents may blunt the rise of sUA levels. Patients should discontinue oral urate-lowering agents and not institute therapy with oral urate-lowering agents while taking KRYSTEXXA.

In the event of anaphylaxis or infusion reaction, the infusion should be slowed, or stopped and restarted at a slower rate.

Inform patients of the symptoms and signs of anaphylaxis, and instruct them to seek immediate medical care should anaphylaxis occur after discharge from the healthcare setting.

CONTRAINDICATIONS: G6PD DEFICIENCY ASSOCIATED HEMOLYSIS AND METHEMOGLOBINEMIA

Screen patients for G6PD deficiency prior to starting KRYSTEXXA. Hemolysis and methemoglobinemia have been reported with KRYSTEXXA in patients with G6PD deficiency. Do not administer KRYSTEXXA to these patients.

GOUT FLARES

An increase in gout flares is frequently observed upon initiation of anti-hyperuricemic therapy, including treatment with KRYSTEXXA. If a gout flare occurs during treatment, KRYSTEXXA need not be discontinued. Gout flare prophylaxis with a non-steroidal anti-inflammatory drug (NSAID) or colchicine is recommended starting at least 1 week before initiation of KRYSTEXXA therapy and lasting at least 6 months, unless medically contraindicated or not tolerated.

CONGESTIVE HEART FAILURE

KRYSTEXXA has not been studied in patients with congestive heart failure, but some patients in the clinical trials experienced exacerbation. Exercise caution when using KRYSTEXXA in patients who have congestive heart failure and monitor patients closely following infusion.

ADVERSE REACTIONS

Please see Full Prescribing Information and Medication Guide for more information.

INDICATIONS AND USAGE

KRYSTEXXA® (pegloticase) is indicated for the treatment of chronic gout in adult patients who have failed to normalize serum uric acid and whose signs and symptoms are inadequately controlled with xanthine oxidase inhibitors at the maximum medically appropriate dose or for whom these drugs are contraindicated.

Important Limitations of Use: KRYSTEXXA is not recommended for the treatment of asymptomatic hyperuricemia.

Important Safety Information

WARNING: ANAPHYLAXIS AND INFUSION REACTIONS

Anaphylaxis and infusion reactions have been reported to occur during and after administration of KRYSTEXXA. Anaphylaxis may occur with any infusion, including a first infusion, and generally manifests within 2 hours of the infusion. However, delayed-type hypersensitivity reactions have also been reported. KRYSTEXXA should be administered in healthcare settings and by healthcare providers prepared to manage anaphylaxis and infusion reactions. Patients should be premedicated with antihistamines and corticosteroids. Patients should be closely monitored for an appropriate period of time for anaphylaxis after administration of KRYSTEXXA. Monitor serum uric acid levels prior to infusions and consider discontinuing treatment if levels increase to above 6 mg/dL, particularly when 2 consecutive levels above 6 mg/dL are observed.

CONTRAINDICATIONS: G6PD DEFICIENCY ASSOCIATED HEMOLYSIS AND METHEMOGLOBINEMIA

Screen patients for G6PD deficiency prior to starting KRYSTEXXA. Hemolysis and methemoglobinemia have been reported with KRYSTEXXA in patients with G6PD deficiency. Do not administer KRYSTEXXA to these patients.

INDICATIONS AND USAGE

KRYSTEXXA® (pegloticase) is indicated for the treatment of chronic gout in adult patients who have failed to normalize serum uric acid and whose signs and symptoms are inadequately controlled with xanthine oxidase inhibitors at the maximum medically appropriate dose or for whom these drugs are contraindicated.

Important Limitations of Use: KRYSTEXXA is not recommended for the treatment of asymptomatic hyperuricemia.

IMPORTANT SAFETY INFORMATION

WARNING: ANAPHYLAXIS AND INFUSION REACTIONS

Anaphylaxis and infusion reactions have been reported to occur during and after administration of KRYSTEXXA. Anaphylaxis may occur with any infusion, including a first infusion, and generally manifests within 2 hours of the infusion. However, delayed-type hypersensitivity reactions have also been reported. KRYSTEXXA should be administered in healthcare settings and by healthcare providers prepared to manage anaphylaxis and infusion reactions. Patients should be premedicated with antihistamines and corticosteroids. Patients should be closely monitored for an appropriate period of time for anaphylaxis after administration of KRYSTEXXA. Monitor serum uric acid levels prior to infusions and consider discontinuing treatment if levels increase to above 6 mg/dL, particularly when 2 consecutive levels above 6 mg/dL are observed.

The risk of anaphylaxis and infusion reactions is higher in patients who have lost therapeutic response.

Concomitant use of KRYSTEXXA and oral urate-lowering agents may blunt the rise of sUA levels. Patients should discontinue oral urate-lowering agents and not institute therapy with oral urate-lowering agents while taking KRYSTEXXA.

In the event of anaphylaxis or infusion reaction, the infusion should be slowed, or stopped and restarted at a slower rate.

Inform patients of the symptoms and signs of anaphylaxis, and instruct them to seek immediate medical care should anaphylaxis occur after discharge from the healthcare setting.

CONTRAINDICATIONS: G6PD DEFICIENCY ASSOCIATED HEMOLYSIS AND METHEMOGLOBINEMIA

Screen patients for G6PD deficiency prior to starting KRYSTEXXA. Hemolysis and methemoglobinemia have been reported with KRYSTEXXA in patients with G6PD deficiency. Do not administer KRYSTEXXA to these patients.

GOUT FLARES

An increase in gout flares is frequently observed upon initiation of anti-hyperuricemic therapy, including treatment with KRYSTEXXA. If a gout flare occurs during treatment, KRYSTEXXA need not be discontinued. Gout flare prophylaxis with a non-steroidal anti-inflammatory drug (NSAID) or colchicine is recommended starting at least 1 week before initiation of KRYSTEXXA therapy and lasting at least 6 months, unless medically contraindicated or not tolerated.

CONGESTIVE HEART FAILURE

KRYSTEXXA has not been studied in patients with congestive heart failure, but some patients in the clinical trials experienced exacerbation. Exercise caution when using KRYSTEXXA in patients who have congestive heart failure and monitor patients closely following infusion.

ADVERSE REACTIONS

Please see Full Prescribing Information and Medication Guide for more information.

  • Terkeltaub R, et al. Arthritis Res Ther. 2006;8(suppl 1):S4.
  • Eleftheriadis T, et al. J Adv Res. 2017;8:555-560.
  • Perez-Ruiz F, et al. Arthritis Rheum. 2002;47:610-613.
  • Schumacher HR, et al. Arthritis Rheum. 2008;59(11):1540-1548.
  • Becker MA, et al. Semin Arthritis Rheum. 2015;45(2):174-183.
  • Becker MA, et al. N Engl J Med. 2005;353(23):2450-2461.
  • Uloric [prescribing information]. Takeda Pharmaceuticals, Inc.
  • Uloric efficacy and safety profile. Uloric website. http://www.goutrx.com/urx/efficacy-safety. Accessed April 9, 2018.
  • Doghramji PP, et al. Postgrad Med. 2012;124(6):98-109.
  • Li-Yu J, et al. J Rheumatol. 2001;28:577-580.
  • Hu M, et al. Ther Clin Risk Manag. 2008;4:1209-1220.
  • Zurampic (lesinurad) [prescribing information]. Ironwood Pharmaceuticals, Inc. July 2017.
  • Probenecid. https://www.pdr.net/drug-summary/Probenecid--probenecid-1984. Accessed October 8, 2018.
  • KRYSTEXXA (pegloticase) [prescribing information] Horizon.
  • Becker LC, et al. Int J Toxicol. 2010;29(suppl 3):84S-97S.
  • Friedman M, et al. Am J Physiol. 1948;155(2):278-281.
  • Caussé E, et al. Clin Nephrol. 2010;73(1):51-57.
  • McDonagh EM, et al. Pharmacogenet Genomics. 2014;24(9):464-476.
  • Yood RA, et al. BMC Res Notes. 2014;7:54.
  • Levey AS, et al. Ann Intern Med. 1999;130(6):461-470.
  • Levey AS, et al. Ann Intern Med. 2009;150(9):604-612.
  • Michels WM, et al. Clin J Am Soc Nephrol. 2010;5(6):1003-1009.
  • Poggio ED, et al. J Am Soc Nephrol. 2005;16(2):459-466.
  • Thiele RG, et al. Rheumatology (Oxford). 2007;46(7):1116-1121.
  • Rees F, et al. Nat Rev Rheumatol. 2014;10(5):271-283.
  • Schett G, et al. RMD Open. 2015;1(suppl 1):e000046.
  • Naredo E, et al. Ann Rheum Dis. 2014;73(8):1522-1528.
  • Dalbeth N, et al. BMC Musculoskelet Disord. 2013;14:363.
  • Dalbeth N, et al. Arthritis Rheum. 2010;62(5):1549-1556.
  • Bongartz T, et al. Ann Rheum Dis. 2015;74(6):1072-1077.